Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: The ISIS randomized controlled trial

JAMA

Volumn 307, Issue 21, 2012, Pages 2269-2277

  Rosenfeld, Margaret ^a,b   Ratjen, Felix ^c   Brumback, Lyndia ^b   Daniel, Stephen ^b   Rowbotham, Ron ^a   McNamara, Sharon ^a   Johnson, Robin ^d   Kronmal, Richard ^b   Davis, Stephanie D ^d,e  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HYPER SAL; LEVALBUTEROL; PLACEBO; SALBUTAMOL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; BREATHING RATE; CANADA; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED RESPIRATORY DOMAIN SCORE; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INFANT; INTESTINE OBSTRUCTION; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; OXYGEN SATURATION; PARALLEL DESIGN; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM PROLAPSE; SCORING SYSTEM; STOMACH PAIN; UNITED STATES; VOMITING; WHEEZING;

EID: 84861892411     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.5214     Document Type: Article

References (30)

1. Ranganathan SC, Stocks J, Dezateux C, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 2004;169(8):928-933. (Pubitemid 38457319)
2. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med. 2007;175(9):943-950. (Pubitemid 46684705)
3. Mott LS, Park J, Murray CP, et al; AREST CF. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT [published online ahead of print December 26, 2011]. Thorax. 2011. doi:10.1136/thoraxjnl-2011-200912.
4. Davis SD, Rosenfeld M, Kerby GS, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med. 2010;182(11):1387-1397.
5. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261(1):5-16. (Pubitemid 46046468)
6. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol. 2007;35(1):116-129. (Pubitemid 46328419)
7. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241-250. (Pubitemid 43113029)
8. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009;(2):CD001506.
9. Elkins MR, Robinson M, Rose BR, et al National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229-240. (Pubitemid 43113028)
10. Rosenfeld M, Davis S, Brumback L, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol. 2011;46(7):666-671.
11. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43(11):1100-1106.
12. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol. 2007;42(5):471-476. (Pubitemid 46700947)
13. Cystic Fibrosis Foundation. National Patient Registry 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2011.
14. Quittner AL, Sweeny S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000;25(6):403-414.
15. West SE, Zeng L, Lee BL, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287(22):2958-2967. (Pubitemid 34619999)
16. Stocks J, Godfrey S, Beardsmore C, Bar-Yishay E, Castile R; ERS/ATS Task Force on Standards for Infant Respiratory Function Testing; European Respiratory Society/American Thoracic Society. Plethysmographic measurements of lung volume and airway resistance. Eur Respir J. 2001;17:302-312.
17. Castile R, Filbrun D, Flucke R, Franklin W, McCoy K. Adult-type pulmonary function tests in infants without respiratory disease. Pediatr Pulmonol. 2000;30(3):215-227.
18. American Thoracic Society; European Respiratory Society. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005;172(11):1463-1471.
19. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556. (Pubitemid 10242750)
20. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996;21(2):77-83. (Pubitemid 26098513)
21. Dmello D, Nayak RP, Matuschak GM. Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis. BMJ Open. 2011;1(1):e000019.
22. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):370-377. (Pubitemid 47330874)
23. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002;166(12, pt 1):1550-1555. (Pubitemid 36015948)
24. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345-352. (Pubitemid 32144560)
25. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-1715.
26. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847-856.
27. van Ewijk BE, van der Zalm MM, Wolfs TF, van der Ent CK. Viral respiratory infections in cystic fibrosis. J Cyst Fibros. 2005;4(suppl 2):31-36. (Pubitemid 41131326)
28. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008;(4):CD006458.
29. Rosenfeld M, Emerson J, McNamara S, et al EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol. 2010;45(9):934-944.
30. Saiman L, Siegel J; Cystic Fibrosis Foundation. Infection control recommendations for patientswith cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-topatient transmission. Infect Control Hosp Epidemiol. 2003;24(5)(suppl):S6-S52. (Pubitemid 36617275)